REQUEST A DEMO
Total
USD $0.00
Search more companies

Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja (Serbia)

Main Activities: Research and Development in Nanotechnology
Full name: Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja Profile Updated: October 16, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja is an enterprise in Serbia, with the main office in Belgrade. It operates in the Research and Development in Nanotechnology sector. The company was established on 2002. Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja currently employs 156 (2023) people. In 2023, the company reported a net sales revenue increase of 16.2%. During that time, Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja’s total assets grew by 24.47%. In, 2023, the company’s net profit margin decreased by 10.35%.

Headquarters
TADEUSA KOSCUSKA 1 1
Belgrade; Belgrade; Postal Code: http://www.mocbilja.rs

Contact Details: Purchase the Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja report to view the information.

Website: http://CUBE_PROFILES_YU

Basic Information
Total Employees:
Purchase the Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja report to view the information.
Outstanding Shares:
Purchase the Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja report to view the information.
Registered Capital:
Purchase the Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja report to view the information.
Incorporation Date:
2002
Key Executives
Purchase this report to view the information.
Legal Representative
Company Performance
Financial values in the chart are available after Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
16.2%
Total operating revenue
8.99%
Operating profit (EBIT)
-93.32%
EBITDA
-73.64%
Net Profit (Loss) for the Period
-99.64%
Total assets
24.47%
Total equity
0.08%
Operating Profit Margin (ROS)
-11.4%
Net Profit Margin
-10.35%
Return on Equity (ROE)
-21.44%
Debt to Equity Ratio
21.22%
Quick Ratio
0.28%
Cash Ratio
0.07%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?